intellia phase 1 2021 - SERP Analysis

https://ir.intelliatx.com/news-releases/news-release-details/intellia-announces-positive-two-year-follow-data-ongoing-phase-1

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-positive-three-year-data-phase-1

https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing

https://ir.intelliatx.com/news-releases/news-release-details/intellia-presents-new-interim-data-ongoing-phase-1-study-ntla

https://www.nejm.org/doi/full/10.1056/NEJMoa2107454

https://ir.intelliatx.com/news-releases/news-release-details/intellia-announces-first-clinical-evidence-ongoing-phase-1-study

https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-updated-phase-1-data

https://www.globenewswire.com/news-release/2021/06/26/2253514/0/en/Intellia-and-Regeneron-Announce-Landmark-Clinical-Data-Showing-Deep-Reduction-in-Disease-Causing-Protein-After-Single-Infusion-of-NTLA-2001-an-Investigational-CRISPR-Therapy-for-Tr.html

https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-present-updated-interim-data-phase-1

https://pubmed.ncbi.nlm.nih.gov/34215024/

https://www.biospace.com/intellia-therapeutics-to-present-interim-clinical-data-from-ongoing-phase-1-study-of-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-at-the-2021-peripheral-nerve-society-annual-meeting

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-expansion-ongoing-phase-1-study

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-4

https://www.globenewswire.com/news-release/2021/06/04/2241982/0/en/Intellia-Therapeutics-to-Present-Interim-Clinical-Data-from-Ongoing-Phase-1-Study-of-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-at-the-2021-Peripheral-Nerve-Soci.html

https://www.cgtlive.com/view/first-patient-dosed-phase-3-trial-intellia-therapeutics-hereditary-angioedema-gene-editing-therapy-ntla-2002

https://www.oligotherapeutics.org/wp-content/uploads/2021/08/A-Momentous-CRISPR-Milestone-was-Achieved-with-Remarkable-Results.pdf

https://www.fiercebiotech.com/biotech/intellias-crispr-therapy-durability-attr-amyloidosis-dose-clinical-trial

https://firstwordpharma.com/story/5474687

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-patient-dosed-phase-12

https://www.biopharmadive.com/news/biotech-clinical-trials-watch-q3-q4-2021/601896/

https://clinicaltrials.gov/study/NCT04601051

https://www.sec.gov/Archives/edgar/data/1652130/000095017022000098/ntla-ex99_1.htm

https://globalgenes.org/raredaily/intellia-and-regeneron-report-positive-updated-phase-1-data-from-study-of-in-vivo-gene-editing-therapy-for-attr-amyloidosis/

https://crisprqc.com/clinical-crispr-success-demonstrates-need-for-quality-control/

https://checkorphan.org/news/intellia-therapeutics-to-present-interim-clinical-data-from-ongoing-phase-1-study-of-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-at-the-2021-peripheral-nerve-society-annual-meeting/

https://www.clinicaltrialsarena.com/news/intellias-gene-editing-therapy-shows-early-potential-in-rare-heart-condition/

https://en.wikipedia.org/wiki/Intellia_Therapeutics

https://trialstat.com/2021/09/intellia-therapeutics-announces-u-s-fda-acceptance-of-investigational-new-drug-application-for-ntla-5001-its-crispr-cas9-engineered-tcr-t-cell-candidate-for-acute-myeloid-leukemia/

https://ir.intelliatx.com/news-releases/news-release-details/intellia-announces-positive-clinical-proof-concept-data-redosing

https://innovativegenomics.org/news/crispr-clinical-trials-2024/

https://oneamyloidosisvoice.com/news-meeting/intellia-and-regeneron-announce-updated-phase-1-data-demonstrating-single-dose-ntla

https://ipira.berkeley.edu/news-archive?field_openberkeley_news_type_tid_op=or&field_openberkeley_news_type_tid%5B42%5D=42

https://www.biopharmadive.com/news/intellia-crispr-attr-amyloidosis-nex-z-data-nejm/733186/

https://www.cgtlive.com/view/attr-amyloidosis-crispr-therapy-odd

https://www.eurekalert.org/news-releases/538382

https://www.fiercebiotech.com/biotech/intellias-1st-ex-vivo-cell-therapy-aml-secures-fda-orphan-drug-status-week-after-trial

https://crisprmedicinenews.com/company/card/intellia-therapeutics/

https://www.mmm-online.com/home/channel/intellias-crispr-based-drug-for-hae-passes-phase-1-test/

https://pubs.acs.org/doi/10.1021/cen-09944-cover6

https://www.stocktitan.net/news/NTLA/intellia-therapeutics-to-present-new-clinical-data-from-the-phase-1-f4j5igm00x0u.html

https://arci.org/category/clinical-trials/page/3/

https://clin.larvol.com/trial-detail/NCT05066165

https://www.reddit.com/r/Biotechplays/comments/1dy7uxf/trying_to_understand_intellia_ntla/

https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001693-33/DE

https://www.rarediseaseadvisor.com/news/genome-editing-therapy-attr-ntla-2001-potential-redosing/

https://www.sec.gov/Archives/edgar/data/1652130/000119312521201044/d197054dex991.htm

https://dev.amyloidosis.org/news-stories/published-27-march-2023intellia-and-regeneron-present-updated-interim-data-from-phase-1-study-of-crispr-based-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-demonstrating-that-deep-se/

https://clinicaltrials.gov/study/NCT05120830

https://theconferenceforum.org/editorial/intellia-therapeuticss-cmo-on-exciting-developments-in-in-vivo-gene-editing

https://www.clinicaltrialvanguard.com/news/intellia-announces-positive-two-year-data-from-ongoing-phase-1-study-of-ntla-2002-for-attr-amyloidosis/

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-highlights-strategic-priorities-and

https://www.clinicaltrialsarena.com/news/intellia-therapeutics-crispr-first-patient-pivotal/

https://synapse.patsnap.com/article/intellia-therapeutics-authorized-for-phase-12-trial-of-ntla-3001-for-alpha-1-antitrypsin-deficiency

https://avencell.com/blackstone-life-sciences-cellex-cell-professionals-and-intellia-therapeutics-launch-new-car-t-cell-company/

https://globalgenes.org/raredaily/intellia-reports-positive-two-year-follow-up-data-in-phase-1-attr-study/

https://pubmed.ncbi.nlm.nih.gov/39445704/

https://investor.regeneron.com/node/26391/pdf

https://trialstat.com/2024/02/intellia-therapeutics-announces-publication-of-positive-interim-phase-1-data-for-ntla-2002-in-patients-with-hereditary-angioedema-in-the-new-england-journal-of-medicine/

https://www.2minutemedicine.com/intellia-therapeutics-ntla-2002-crispr-based-therapy-reduces-rates-of-hereditary-angioedema-hae-attacks/

https://www.linkedin.com/posts/intelliatx_sciences-2021-breakthrough-of-the-year-activity-6879441158263619584-f-ue?trk=public_profile_like_view

https://crisprmedicinenews.com/category/transthyretin-amyloidosis-attr/

https://pharmaceuticalintelligence.com/2021/02/19/first-single-course-curative-crispr-shot-by-intellia-rivals-alnylam-ionis-and-pfizer/

https://innovativegenomics.org/news/crispr-clinical-trials-2022/

https://arci.org/tag/attr/

https://haei.org/intellia-authorized-to-initiate-phase-1-2-clinical-trial-of-ntla-2002/

https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001693-33/NL

https://www.goodwinlaw.com/en/news-and-events/news/2021/07/07_15-intellia-therapeutics-completes-%24600-million

https://www.nejm.org/doi/abs/10.1056/NEJMoa2405734

https://amyloidosis.org/node/84

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-receives-authorization-initiate-phase-1

https://finance.yahoo.com/news/intellia-therapeutics-announces-fourth-quarter-123000678.html

https://www.rarediseaseadvisor.com/news/intellia-therapeutics-presents-pioneering-data-redosing-ntla-2001/

https://www.oligotherapeutics.org/a-momentous-crispr-milestone-was-achieved-with-remarkable-results/

https://www.tradingview.com/symbols/DUS-38I/ideas/?sort=recent&video=yes

https://www.stocktitan.net/news/NTLA/page-14.html

https://www.prohostbiotech.com/tag/intellia-therapeutics-ntla/

https://www.instagram.com/reel/DCb-WHAiDNW/?hl=en

https://www.linkedin.com/pulse/beginning-something-big-john-leonard?trk=public_post_main-feed-card_feed-article-content

https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/

https://finance.yahoo.com/quote/NTLA/

https://ir.intelliatx.com/press-releases

https://www.prnewswire.com/news-releases/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-causing-protein-after-single-infusion-of-ntla-2001-an-investigational-crispr-therapy-for-transthyretin-attr-amyloidosis-301320471.html

https://www.youtube.com/watch?v=yXSCNfWFEMY

https://medcitynews.com/2021/06/intellias-early-crispr-trial-data-validate-a-drug-pipeline-and-the-gene-editing-field/

https://twitter.com/intelliatweets/status/1408841791156199426

https://www.streetwisereports.com/article/2021/06/28/intellia-shares-rise-49-on-landmark-interim-results-in-phase-1-attr-amyloidosis-trial.html

https://www.instagram.com/reel/C2-JdlkCiYj/

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-receives-us-fda-orphan-drug-designation

https://www.genengnews.com/topics/genome-editing/new-era-of-medicine-researchers-publish-first-positive-clinical-data-for-in-vivo-genome-editing-in-humans/

https://xtalks.com/intellia-gets-fda-clearance-to-start-first-ever-phase-iii-trial-for-an-in-vivo-crispr-drug-3564/

https://angioedemanews.com/news/intellia-seeks-to-advance-its-gene-editing-therapy-to-human-trials/

https://www.healio.com/news/hematology-oncology/20210917/fda-clears-ind-application-for-crispredited-tcell-receptor-therapy-to-treat-aml

https://www.citybiz.co/article/116845/intellia-therapeutics-announces-second-quarter-2021-financial-results-and-highlights-recent-company-progress/

https://fapnewstoday.com/news/pivotal-trials-being-prepped-gene-editing-therapy-ntla-2001/

https://www.nasdaq.com/articles/why-intellia-therapeutics-stock-is-skyrocketing-today-2021-06-28

https://www.prnewswire.com/news-releases/intellia-and-regeneron-announce-initial-data-from-the-cardiomyopathy-arm-of-ongoing-phase-1-study-of-ntla-2001-an-investigational-crispr-therapy-for-the-treatment-of-transthyretin-attr-amyloidosis-301625784.html

https://news.bloomberglaw.com/health-law-and-business/liver-study-results-show-how-crispr-could-transform-treatment

https://www.investing.com/equities/intellia-therapeutics-inc

https://www.barrons.com/articles/gene-editing-data-intellia-51624713237